Soligenix (SNGX) Common Equity (2010 - 2026)
Soligenix's (SNGX) quarterly Common Equity came in at $3.1 million in Q1 2026, down 20.73% YoY from $3.9 million in Q1 2025, and down 41.61% on a QoQ basis from $5.3 million in Q4 2025.
Soligenix (SNGX) Common Equity (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Common Equity data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Common Equity fell 20.73% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 20.73% YoY) and the FY2025 annual result came in at $5.3 million, up 28.51% from the prior year.
- Common Equity slipped to $3.1 million in Q1 2026, from $5.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $7.6 million in Q3 2025 to a low of -$3.4 million in Q1 2023.
- A 5-year average of $3.2 million and a median of $3.9 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity sank 151.44% — and 2025, when it jumped 407.3%.
- Tracing SNGX's Common Equity over 5 years: stood at -$2.5 million in 2022, then surged by 202.09% to $2.5 million in 2023, then jumped by 63.26% to $4.1 million in 2024, then grew by 28.51% to $5.3 million in 2025, then sank by 41.61% to $3.1 million in 2026.
- The last three Common Equity figures came in at $3.1 million (Q1 2026), $5.3 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.79 Bn |
| 10 | Soligenix | 6.26 Mn | 6.26 Mn | - | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.65 Mn |
| Mar 31, 2026 | 3.09 Mn |
| Dec 31, 2025 | 5.29 Mn |
| Sep 30, 2025 | 7.60 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 5.94 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Mar 31, 2024 | 768,372.00 |
| Dec 31, 2023 | 2.52 Mn |
| Sep 30, 2023 | 4.22 Mn |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | -3.39 Mn |
| Dec 31, 2022 | -2.47 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 4.21 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 10.72 Mn |
| Sep 30, 2021 | 15.05 Mn |